30 closest matches · ranked by relevance
HIV Infections
Primary: Time to Treatment Failure (PI Comparison) — 16; 16; 40; 24 weeks — p=<0.01
Human Immunodeficiency Virus (HIV)
Primary: Time-weighted Mean Change From Baseline Plasma HIV-RNA. — -2.59; -2.69; -2.39 log copies/mL
HIV Infections
Primary: Percent of Participants With Regimen Failure, Defined as a Confirmed Virologic Failure or Discontinuation of Randomized NRTI Component of Study Treatment — 26.0; 29.8…
Antiretroviral Treatment Outcomes
Primary: The Antiretroviral Treatment Failure Rate at 12 Months. — 4; 5 participants — p=1.00
Severely Immunocompromised HIV Patients
Primary: Early Mortality — 9; 13 Participants
HIV Infections
Primary: Confirmed Virologic Failure at or Prior to Week 48 — 95; 105; 34; 23 participants — p=0.133
HIV · AIDS
Primary: Number and Percentage of Patients Achieving Virologic Resuppression — 256; 263 Participants
HIV Infections
Primary: Participants With Plasma HIV RNA < 200 Copies/mL 48 Weeks After Randomization — 219; 223 participants
HIV Infections
Primary: Number of Patients With Virological Failure (Two Consecutive Measures of HIV-RNA Higher Than 50 Copies/mL or a Single Measure Higher Than 1000 Copies/mL) Within 48 Weeks…
Human Immunodeficiency Virus
Primary: Number of Patients With Virus That Develop Mutations Conferring Resistance to Lopinavir/Ritonavir, NRTIs or NNRTIs — 137; 68; 55; 122 Participants
HIV Infections
Primary: Mean Adherence, as Measured by Electronic Drug Monitors (EDM) — 96.5; 84.5; 96.4; 84.1 percentage of doses taken on time
HIV Infections
Primary: The Primary Outcome of This Study is the Proportion of Patients Having Detectable HIV-1 RNA Using the Single Copy Assay After 48 Weeks of Treatment and the Study…
HIV Infection
Primary: Composite Endpoint of AIDS, Serious Non-AIDS Diagnoses, and All-cause Mortality — 133; 215 Participants
HIV Infections
Primary: Summary of Change From Baseline in Alanine Aminotransferase (ALT) to Last Value on Treatment — 1.0 IU/L
HIV Infections
Primary: Number of Participants With Treatment Emergent Adverse Events (AE) and All Serious AEs — 168; 110; 51; 10 participants
HIV Infections
Primary: Virological Suppression at 24 Weeks — 55; 53; 53 Participants
Hepatitis B, Chronic
Primary: Number of Participants With HBV DNA <20 IU Per mL — 257; 261; 257; 256 Participants
HIV-1 Infection
Primary: Percentage of Participants With Successful Virological Suppression at Weeks 48 and 96 — 99.4; 98.7 percentage of participant
HIV Infections
Primary: Change From Baseline in CD4 Count at 48 Weeks — 192; 205 cells/uL
HIV Infection
Primary: Annual Rate of Change in Right Common Carotid Artery Intima-media Thickness (CIMT) — 8.2; 10.7; 12.9 micron/year — p=0.013
HIV · HIV Infections
Primary: Mean Change in Estimated Ultrasensitive Plasma HIV RNA Levels Between Baseline and Week 24 — 66 fold decrease in signal/cutoff ratio
HIV Infections
Primary: Mean Self-reported Adherence Score (%) Over a One-month Recall — 97.5; 98.2 percentage of adherence score — p=0.52
HIV
Primary: Progression to AIDS or Death in tx naïve Pts With Adv HIV dx in the Four Randomly Assigned Regimens. — 93; 77; 70; 80 participants
HIV Infections
Primary: Proportion of Women With Plasma HIV-1 RNA Viral Load Less Than 200 Copies/mL at Delivery — .84; .94 Proportion — p=0.001
Women's Health · HIV Infection · Genital Diseases, Female
Primary: CD4+ to CD8+ T Cell Ratio in Cervical Biopsies — 0.46; 0.52 Cervical CD4+:CD8+ T cell ratio — p=0.6
HIV Infections
Primary: HIV-RNA Levels — 0; 24; 10; 107 participants — p=<0.001
HIV-1-infection
Primary: 48 Weeks Treatment Durability — 76.0 percentage of participants
HIV
Primary: ART Initiation — 181; 63 participants
HIV Infections
Primary: Total Treatment-free Time to Initiation of Permanent HAART — 18; 18 months
Human Immunodeficiency Virus
Primary: LCM vs CDM: Disease Progression to a New WHO Stage 4 Event or Death — 47; 39 participants — p=0.59